Sanjeeb Mukherjee And Sushmi Dey

Parliamentary panel again says phase out STT

The Committee, in an earlier report on the Direct Taxes Code (DTC) Bill, had favoured abolition of STT.

'Monsoon likely to be normal this year'

Expected to be over 100% of long average period.

Pharma R&D: Basic drug research only a part

Spending allocation covers salaries, consultancy, litigation, material expense and regulatory costs.

Cipla's petition against drug price revision rejected

The department of pharmaceuticals turned down a review petition by drugmaker Cipla against a price fixation order by the National Pharmaceutical Pricing Authority, slashing the price of Dytor Plus, a medicine for kidney and heart ailments.

Cipla's petition against drug price revision rejected

TV owners might have to pay licensing fee

Television owners might have to again shell out a licence fee- this time to fund state-owned Prasar Bharati, which runs Doordarshan and All India Radio, if a government committee has its way.

Novartis has 219 patents in India

Data contradict Swiss drug major's claim that India does not respect IPR.

'Judgment will ensure no ever-greening of patents'

Though the legal battle over Glivec's patentability may be over for now, Y K Sapru, the man spearheading the fight against Swiss multinational Novartis, isn't resting.

Merck moves HC against Glenmark

Merck alleges violation of its patent for anti-diabetes drugs Januvia and Janumet.

Now, drug prices may be capped at time of launch

The idea is to ensure drug companies do not gold-plate drugs to exorbitantly raise prices while introducing those in the market.

For now, Bihar likely to get just a 'backward' boost

Chief Minister Nitish Kumar's demand for special-category status still looks a far cry.

Coming soon: 'Milk City' in Delhi

'Milk City' plans to distribute milk at rates which are almost Rs 7-10 a litre less than the current prices.

Revised food security Bill gives states more power

It does not bar any state or the Centre from continuing or launching other food-based schemes.

Ranbaxy may get approval for multi-billion dollar drug

If it gets the USFDA nod, the sales would help to pull the company out of the red.

Recent drug recalls worry investors

Many say trend could lead to concerns on manufacturing quality in Indian facilities.

MCA to rope in Google, BSNL for investors' awareness

Through messages via the BSNL network, the ministry plans to spread awareness among the public and ask people not to invest in suspicious companies.

Drug makers charged with overcharging of Rs 2,362 cr

National Pharmaceutical Pricing Authority names Cipla, Dr Reddy's Labs and Ranbaxy among those.

Health care majors go online to extend reach

Major hospital chains such as Max Healthcare, Apollo and Fortis are going online in a big way, to extend their operations into smaller towns and cities.

Diagnostic chains look to smaller towns

Not far back, in 2010, SRL Diagnostics, promoted by former Ranbaxy promoters Malvinder and Shivinder Singh, acquired the diagnostic services business of Piramal Healthcare for Rs 600 crore (Rs 6 billion).

Imported insulin to cost more

Department of Pharmaceuticals asks NPPA to review Eli Lilly product prices.